Spironolactone
Product Images NDC 53002-4720

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 53002-4720). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl530024720)

Label Image (Lbl530024720)
The image shows a white drug product label for Spironolactone 25mg Tablets by RPK Pharmaceuticals, Inc. It is designed for a bottle containing 30 tablets. The label includes dosage instructions with blank spaces for dose and frequency to be filled by a healthcare provider. It also has patient information, lot number, expiration date, barcode, and dispensing details. The label advises to take with food and warns against potassium supplement use without approval.*
FDA Label Image

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)
A Kaplan-Meier survival probability curve comparing Spironolactone and Placebo groups over 48 months. The y-axis shows survival probability from 0 to 1, and the x-axis shows time in months. Spironolactone group (n=822) maintains a higher survival probability compared to Placebo (n=841). A log-rank p-value less than 0.001 is indicated.*
FDA Label Image

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)
A forest plot showing hazard ratios (HR) and 95% confidence intervals (CI) for various subgroups in a study comparing Spironolactone to placebo. The subgroups include age, sex, race, LVEF %, heart failure type, NYHA class, diabetes status, serum creatinine levels, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. Each subgroup's HR and CI are plotted with a central marker and horizontal line, alongside sample size (N) and percentage (%) values. The graph indicates whether Spironolactone or placebo is favored across subgroups.*
FDA Label Image

Chemical Structure (Spironolactone Structure Image)

Chemical Structure (Spironolactone Structure Image)
Chemical structure of spironolactone, showing its steroid-based molecular framework with ketone and thioester functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.